LMNB2 and neoplasm: Simultaneously, a deeper understanding of tumor molecular subtypes, for example, those where high LMNB2 expression drives PD-L1 upregulation [48], also helps screen patient populations most likely to benefit from ICI therapy with relatively controllable rejection risks, enabling true risk-stratified management.